Literature DB >> 9003344

Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide.

R P Danis1, D P Bingaman, Y Yang, B Ladd.   

Abstract

PURPOSE: The authors tested the antiangiogenic properties of intravitreally administered triamcionolone acetonide in a pig model of preretinal neovascularization to determine the effectiveness of this therapy in preventing neovascularization.
METHODS: In 14 eyes of seven pigs, branch retinal vein occlusions were created in a standardized manner using photodynamic thrombosis with rose bengal dye and thermal burns from the argon green laser. Intravitreal injection of approximately 4 mg of triamcinolone acetonide was performed in one eye of each animal, and eyes were followed clinically for 12 weeks with ophthalmoscopy and fundus photography. A standardized grading system was developed to permit masked assessment of disc proliferations from fundus stereophotographs. After death, all neovascularization was confirmed histopathologically and a final grade was assigned to each eye. Statistical analysis employed use of a nonparametric test of the paired data.
RESULTS: Significant inhibition of neovascularization was observed in triamcinolone-treated eyes (P = 0.0156). Although none of the steroid-injected eyes demonstrated clinically evident new vessels, histopathologic and photographic analysis results demonstrated fine new vessels on the optic disc in four eyes. In all of the untreated eyes, neovascularization of a moderate (II) to high (III to IV) grade developed.
CONCLUSIONS: Intravitreal triamcinolone acetonide effectively inhibited preretinal and optic nerve head neovascularization in the pig model. The grading system used permitted masked assessment of outcome and paired analysis allowed a conclusion to be drawn from a relatively small number of eyes. The mechanisms by which triamcinolone acetonide inhibits neovascularization remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9003344     DOI: 10.1016/s0161-6420(96)30383-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  28 in total

1.  Intraocular pressure after intravitreal injection of triamcinolone acetonide.

Authors:  J B Jonas; I Kreissig; R Degenring
Journal:  Br J Ophthalmol       Date:  2003-01       Impact factor: 4.638

2.  Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration.

Authors:  E Rechtman; R P Danis; L M Pratt; A Harris
Journal:  Br J Ophthalmol       Date:  2004-03       Impact factor: 4.638

3.  Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration.

Authors:  J B Jonas; I Kreissig; R F Degenring
Journal:  Br J Ophthalmol       Date:  2004-12       Impact factor: 4.638

4.  Treatment of recurrent retinal angiomatous proliferation with intravitreal triamcinolone acetonide followed by photodynamic therapy with verteporfin: A retrospective case series.

Authors:  Nicola Cardascia; Claudio Furino; Andrea Ferrara; Francesco Boscia; Giovanni Alessio
Journal:  Curr Ther Res Clin Exp       Date:  2009-06

5.  The problem of pressure elevation associated with intravitreal triamcinolone.

Authors:  M D Conway
Journal:  Br J Ophthalmol       Date:  2006-08       Impact factor: 4.638

6.  Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

Authors:  J B Jonas; I Kreissig; P Hugger; G Sauder; S Panda-Jonas; R Degenring
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

7.  Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema.

Authors:  Figen Batioğlu; Emin Ozmert; Neslihan Parmak; Selcen Celik
Journal:  Int Ophthalmol       Date:  2007-04-24       Impact factor: 2.031

8.  Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation.

Authors:  Neil M Bressler; Allison R Edwards; Roy W Beck; Christina J Flaxel; Adam R Glassman; Michael S Ip; Craig Kollman; Baruch D Kuppermann; Thomas W Stone
Journal:  Arch Ophthalmol       Date:  2009-12

9.  Regression of optic nerve head neovascularization in proliferative diabetic retinopathy after intravitreal triamcinolone. Regression of diabetic optic disc neovascularization after intravitreal triamcinolone.

Authors:  Murat Karacorlu; Hakan Ozdemir; Serra Karacorlu; Nilay Alacali
Journal:  Int Ophthalmol       Date:  2004-03       Impact factor: 2.031

10.  Combined intravitreal bevacizumab and photodynamic therapy with vertiporfin for management of choroidal neovascularization secondary to age-related macular degeneration.

Authors:  Mamdouh M Kabeel; Ashraf M El-Batarny; Mohamed K Tameesh; Moustafa A Abou El Enein
Journal:  Clin Ophthalmol       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.